PMID

Data

Article Title

Organization

Great Therapeutic Potential of Peptidylarginine Deiminase 4 (PAD4) Inhibitors: Treatment of Rheumatoid Arthritis, Epigenetic Tools, Regulation of Pluripotency in Stem Cells, and More.

Therachem Research Medilab (India)

Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation.

The Scripps Research Institute-Florida

Interrogation of the Active Sites of Protein Arginine Deiminases (PAD1, -2, and -4) Using Designer Probes.

University Health Network

Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.

University of South Carolina

The development of N-a-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-a-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.

The Scripps Research Institute

Novel Peptidylarginine Deiminase Type 4 (PAD4) Inhibitors.

Smith, Gambrell & Russell

Novel Macrocyclic Peptidylarginine Deiminase Type 4 (PAD4) Inhibitors.

Smith, Gambrell & Russell

Peptidylarginine deiminases 4 as a promising target in drug discovery.

Zhejiang Ocean University

DNA-Encoded Library Screening as Core Platform Technology in Drug Discovery: Its Synthetic Method Development and Applications in DEL Synthesis.

Daegu-Gyeongbuk Medical Innovation Foundation (Dgmif)

Cellular Activity of New Small Molecule Protein Arginine Deiminase 3 (PAD3) Inhibitors.

Yale University

Chemical Space of DNA-Encoded Libraries.

University of Utah

Synthesis and Biological Evaluation of an Indazole-Based Selective Protein Arginine Deiminase 4 (PAD4) Inhibitor.

Yale University

Inhibitors of protein arginine deiminases and their efficacy in animal models of multiple sclerosis.

University Health Network

Noncovalent Protein Arginine Deiminase (PAD) Inhibitors Are Efficacious in Animal Models of Multiple Sclerosis.

University of Toronto